Stability Failure during FDA inspection: CAPA plan with effectiveness checks
Identifying the symptoms of stability failures is crucial for prompt intervention. Common signals during routine monitoring include:Click to read the full article.
Tips for Dosage Forms & Drug Delivery Systems
Pump Actuation Failure during EU/UK launch supply: method variability vs true product failure assessment
The first step in addressing a potential pump actuation failure is recognizing the signals that indicate a deviation from expected performance. Common symptoms may include:Click to read the full article.
Gmp Gap during lifecycle management: ownership between drug GMP and device QMS
Identifying symptoms or signals that indicate a potential GMP gap in lifecycle management is the first step in a robust investigation. Common indicators may include:Click to read the full article.
Post-Approval Change Failure for combination drug products: ownership between drug GMP and device QMS
Recognition of symptoms related to a post-approval change failure is a crucial first step in any investigation. Symptoms may manifest as deviations, Out of Specification (OOS) results, or even complaints…
Complaint Handling Deficiency during lifecycle management: what inspectors expect and how to fix it
A deficiency in complaint handling often manifests through various symptoms both on the production floor and within the investigative lab environment. Identifying these signals promptly is essential to trigger an…
Pump Actuation Failure during EU/UK launch supply: FDA/MHRA investigation and corrective actions
Recognizing the signals of a pump actuation failure is crucial for initiating an effective investigation. Common symptoms include:Click to read the full article.
Regulatory Classification Issue after device supplier change: risk assessment and change control template
Identifying early signals of a potential regulatory classification issue can prevent escalations that lead to significant compliance risks. Common symptoms include:Click to read the full article.
Gmp Gap after device supplier change: ownership between drug GMP and device QMS
Understanding the initial indicators of potential GMP deficiencies is essential in managing supplier transitions effectively. Common symptoms may include:Click to read the full article.
Leakage Complaint in DPI manufacturing: E&L risk assessment and documentation
Identifying signals related to leakage in DPI manufacturing is critical for initiating timely investigations. Symptoms may manifest as:Click to read the full article.
Assembly Process Validation Failure for drug-device combination products: what inspectors expect and how to fix it
Identifying symptoms associated with assembly process validation failures is the first step toward effective resolution. Symptoms can manifest in various forms, including:Click to read the full article.
Gmp Gap during EMA/MHRA review: risk assessment and change control template
Recognizing symptoms or signals of GMP shortfalls is the first step toward effective resolution. These symptoms may surface during routine processes, internal audits, or inspections. Common signals include:Click to read…
Stability Failure during PAI readiness: batch release impact and documentation pack
Identifying early signals of stability failure is crucial in preventing larger issues that may affect batch release. Symptoms can manifest as deviations observed either in the laboratory or during production…